MSP3
MCID: INC035
MIFTS: 27

Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 (MSP3)

Categories: Bone diseases, Genetic diseases, Mental diseases

Aliases & Classifications for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

MalaCards integrated aliases for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3:

Name: Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 12 15
Multisystem Proteinopathy 3 12
Ibmpfd3 12
Msp3 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0111386

Summaries for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Disease Ontology : 12 An inclusion body myopathy with Paget disease of bone and frontotemporal dementia that has material basis in heterozygous mutation in HNRNPA1 on chromosome 12q13.13.

MalaCards based summary : Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3, also known as multisystem proteinopathy 3, is related to plasmodium falciparum malaria and inclusion body myopathy with early-onset paget disease of bone with or without frontotemporal dementia 2. An important gene associated with Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 is NANP (N-Acetylneuraminic Acid Phosphatase), and among its related pathways/superpathways is Malaria. The drugs Aluminum hydroxide and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and monocytes, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Diseases in the Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2 family:

Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 1 Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3

Diseases related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
# Related Disease Score Top Affiliating Genes
1 plasmodium falciparum malaria 29.6 DHPS DHFR CD40LG
2 inclusion body myopathy with early-onset paget disease of bone with or without frontotemporal dementia 2 28.2 XPO1 SENP7 SAG RHAG NANP MCF2
3 malaria 27.2 SENP7 PDXK NANP MCF2 GYPA DHPS
4 inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 3 11.5
5 inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 2 10.4
6 tetanus 10.3
7 colorectal cancer, hereditary nonpolyposis, type 2 10.3 SURF4 AKR1C2
8 retinohepatoendocrinologic syndrome 10.2 RHAG GYPA
9 rapidly involuting congenital hemangioma 10.2
10 otopalatodigital syndrome spectrum disorder 10.1 RHAG GYPA ACKR1
11 melnick-needles syndrome 10.1 RHAG GYPA ACKR1
12 hereditary elliptocytosis 10.1 RHAG GYPA ACKR1
13 mixed malaria 9.9 PDXK ADIRF
14 focal chorioretinitis 9.8 SAG CD40LG
15 meningococcal meningitis 9.8 DHPS ADIRF
16 neuroretinitis 9.8 SAG CD40LG
17 plasmodium malariae malaria 9.7 NANP DHFR CD40LG
18 choroiditis 9.7 SAG CD40LG
19 yaws 9.7 CD40LG ADIRF
20 necrotizing ulcerative gingivitis 9.7 SLURP1 CD40LG
21 chorioretinitis 9.6 SAG DHFR CD40LG
22 plasmodium vivax malaria 9.6 DHFR CD40LG ACKR1
23 ebola hemorrhagic fever 9.5 CD40LG ADIRF
24 congenital toxoplasmosis 9.5 DHFR CD40LG
25 pneumocystosis 9.4 DHPS DHFR CD40LG
26 retinal vasculitis 9.4 SAG CD40LG
27 inclusion body myopathy with early-onset paget disease of bone with or without frontotemporal dementia 1 8.6 XPO1 SENP7 NANP MCF2 GYPA DHPS
28 parasitic protozoa infectious disease 8.2 NANP MCF2 GYPA DHPS DHFR CD40LG
29 inclusion body myopathy with paget disease of bone and frontotemporal dementia 7.2 XPO1 SURF4 SENP7 SAG RHAG NANP

Graphical network of the top 20 diseases related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3:



Diseases related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3

Symptoms & Phenotypes for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

GenomeRNAi Phenotypes related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.55 PDXK
2 Decreased viability GR00221-A-2 9.55 PDXK
3 Decreased viability GR00221-A-3 9.55 PDXK
4 Decreased viability GR00221-A-4 9.55 PDXK
5 Decreased viability GR00240-S-1 9.55 ADIRF CD40LG
6 Decreased viability GR00249-S 9.55 DHFR SENP7
7 Decreased viability GR00381-A-1 9.55 ADIRF DHFR MCF2 NANP
8 Decreased viability GR00386-A-1 9.55 ABRA GYPA XPO1
9 Decreased viability GR00402-S-2 9.55 NANP XPO1

Drugs & Therapeutics for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Drugs for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
2 Vaccines Phase 2
3 Immunologic Factors Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali. Unknown status NCT00652275 Phase 2
2 Phase 2B Double Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of MSP3-LSP Vaccine Candidate Adjuvanted in Aluminium Hydroxide (AIOH) Against Plasmodium Falciparum Clinical Malaria in Healthy Children Aged 12-48 Months in Mali Completed NCT01341704 Phase 2
3 A Double Blind, Randomized, Controlled Phase Ib Field Trial in 12 to 24 Month Old Children in Tanzania to Evaluate the Safety and Immunogenicity of Candidate Malaria Vaccine MSP 3 Versus Hepatitis B Vaccine Unknown status NCT00469651 Phase 1
4 Assessment of the Safety and Immunogenicity of the Recombinant Lactococcus Lactis Hybrid GMZ2 [GLURP+MSP3] a Malaria Vaccine in Healthy Adult Volunteers. A Phase I, Double-Blind, Randomised, Dose-Selection, Unicentre Trial Unknown status NCT00397449 Phase 1
5 A Single Centre, Randomised Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Lactococcus Lactis Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine Versus Rabies Vaccine in Healthy Gabonese Adult Volunteers Unknown status NCT00424944 Phase 1
6 A Phase I, Randomized, Controlled, Double-Blind, Single Centre Trial to Evaluate the Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years Unknown status NCT00703066 Phase 1
7 Randomized, Controlled, Dose Escalation Phase Ib Trial of MSP 3 LSP Adjuvanted in Aluminium Hydroxide Versus Hepatitis Bin 12 to 24 Month Old Children in Burkina Faso. Unknown status NCT00452088 Phase 1

Search NIH Clinical Center for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3

Genetic Tests for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Anatomical Context for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

MalaCards organs/tissues related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3:

40
Bone, Testes, Monocytes

Publications for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Articles related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3:

(show top 50) (show all 133)
# Title Authors PMID Year
1
Measuring antibody avidity to Plasmodium falciparum merozoite antigens using a multiplex immunoassay approach. 61
32357882 2020
2
Schistosoma haematobium infection modulates Plasmodium falciparum parasite density and antimalarial antibody responses. 61
32020650 2020
3
Stage-specific Plasmodium falciparum immune responses in afebrile adults and children living in the Greater Accra Region of Ghana. 61
32041620 2020
4
Sero-diagnostic potential of Plasmodium falciparum recombinant merozoite surface protein (MSP)-3 expressed in silkworm. 61
31201923 2019
5
Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort. 61
31185998 2019
6
Analysis of antibody responses to selected Plasmodium falciparum merozoite surface antigens in mild and cerebral malaria and associations with clinical outcomes. 61
30580455 2019
7
Transcriptome profiling of Plasmodium vivax in Saimiri monkeys identifies potential ligands for invasion. 61
30872477 2019
8
Anti-MSP11 IgG inhibits Plasmodium falciparum merozoite invasion into erythrocytes in vitro. 61
30385417 2019
9
A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01 E on blood stage immunity in young Kenyan children. 61
31168483 2019
10
Association of Antibodies to VAR2CSA and Merozoite Antigens with Pregnancy Outcomes in Women Living in Yaoundé, Cameroon. 61
29986889 2018
11
Plasmodium falciparum MSP3 Exists in a Complex on the Merozoite Surface and Generates Antibody Response during Natural Infection. 61
29760216 2018
12
Identification of target proteins of clinical immunity to Plasmodium falciparum in a region of low malaria transmission. 61
29217416 2018
13
Dynamics of anti-MSP3 and Pfs230 antibody responses and multiplicity of infection in asymptomatic children from southern Ghana. 61
29304870 2018
14
Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against Plasmodium falciparum malaria during infancy: A birth cohort study in Benin. 61
28991911 2017
15
The GMZ2 malaria vaccine: from concept to efficacy in humans. 61
28699823 2017
16
Statistical prediction of immunity to placental malaria based on multi-assay antibody data for malarial antigens. 61
28962616 2017
17
Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso. 61
28886727 2017
18
Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite. 61
28646324 2017
19
Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana. 61
28835262 2017
20
An analytical approach to reduce between-plate variation in multiplex assays that measure antibodies to Plasmodium falciparum antigens. 61
28716094 2017
21
Pooled-DNA sequencing identifies genomic regions of selection in Nigerian isolates of Plasmodium falciparum. 61
28662682 2017
22
Whole-genome sequencing of a Plasmodium vivax clinical isolate exhibits geographical characteristics and high genetic variation in China-Myanmar border area. 61
28166727 2017
23
Individuals living in a malaria-endemic area of Cameroon do not have an acquired antibody response to Plasmodium falciparum histidine-rich protein 2. 61
28148260 2017
24
An outbreak of locally acquired Plasmodium vivax malaria among migrant workers in Oman. 61
28695821 2017
25
Genetic clustering and polymorphism of the merozoite surface protein-3 of Plasmodium knowlesi clinical isolates from Peninsular Malaysia. 61
28049516 2017
26
Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity. 61
27185785 2016
27
Multiple Plasmodium falciparum Merozoite Surface Protein 1 Complexes Mediate Merozoite Binding to Human Erythrocytes. 61
26823464 2016
28
Acquired immune responses to three malaria vaccine candidates and their relationship to invasion inhibition in two populations naturally exposed to malaria. 61
26850066 2016
29
Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity. 61
26541134 2016
30
Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy. 61
27427762 2016
31
The Plasmodium gaboni genome illuminates allelic dimorphism of immunologically important surface antigens in P. falciparum. 61
26296605 2015
32
Asymptomatic Plasmodium falciparum infection in children is associated with increased auto-antibody production, high IL-10 plasma levels and antibodies to merozoite surface protein 3. 61
25889717 2015
33
[IgG responses to candidate malaria vaccine antigens in the urban area of Dakar (Senegal): evolution according to age and parasitemia in patients with mild symptoms]. 61
25925805 2015
34
Is Fc gamma receptor IIA (FcγRIIA) polymorphism associated with clinical malaria and Plasmodium falciparum specific antibody levels in children from Burkina Faso? 61
25447268 2015
35
Parasite Specific Antibody Increase Induced by an Episode of Acute P. falciparum Uncomplicated Malaria. 61
25906165 2015
36
Genetic and genomic diversity studies of Acacia symbionts in Senegal reveal new species of Mesorhizobium with a putative geographical pattern. 61
25658650 2015
37
The origin and diversification of the merozoite surface protein 3 (msp3) multi-gene family in Plasmodium vivax and related parasites. 61
24862221 2014
38
Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. 61
24980799 2014
39
New antigens for a multicomponent blood-stage malaria vaccine. 61
25080477 2014
40
A unique missense allele of BAF155, a core BAF chromatin remodeling complex protein, causes neural tube closure defects in mice. 61
24170322 2014
41
Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum. 61
24218484 2014
42
Plasmodium falciparum merozoite surface protein 3: oligomerization, self-assembly, and heme complex formation. 61
24362023 2014
43
Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP). 61
25238160 2014
44
The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. 61
23624363 2013
45
Motor neuron involvement in multisystem proteinopathy: implications for ALS. 61
23635965 2013
46
Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia. 61
23383869 2013
47
Development and evaluation of a multiplex screening assay for Plasmodium falciparum exposure. 61
22835432 2012
48
Using community-owned resource persons to provide early diagnosis and treatment and estimate malaria burden at community level in north-eastern Tanzania. 61
22554149 2012
49
Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso. 61
22439695 2012
50
Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes. 61
22248820 2012

Variations for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Expression for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Search GEO for disease gene expression data for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3.

Pathways for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Pathways related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.5 GYPA CD40LG ACKR1

GO Terms for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Cellular components related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.44 XPO1 SURF4 SAG RAP2A PDXK NUP42

Biological processes related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein export from nucleus GO:0006611 8.62 XPO1 NUP42

Molecular functions related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear export signal receptor activity GO:0005049 8.62 XPO1 NUP42

Sources for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....